Overview

The EPIVER Randomized Controlled Trial

Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
0
Participant gender:
All
Summary
The trial aims to estimate the efficacy and safety of the intracoronary administration of adrenalin, verapamil, as well as their combination compared to standard treatment in patients with STEMI and refractory coronary no-reflow despite conventional treatment during percutaneous coronary intervention (PPCI)
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Tomsk National Research Medical Center of the Russian Academy of Sciences
Treatments:
Epinephrine
Epinephryl borate
Racepinephrine
Verapamil
Criteria
Inclusion Criteria:

- patients with ST-elevation myocardial infarction

- Infarct-related artery TIMI flow grade 0-2 during the interventional procedure after
the initial opening of the vessel.

- Written the informed consent to participate in research

Exclusion Criteria:

- Unable to undergo or contra-indications for MRI or SPECT